EUCTR2016-003991-27-NL进行中(未招募)1 期
MAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients - DAPAMAAST
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中(未招募)
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Provision of signed and dated, written informed consent prior to any study specific procedures
- •Post-menopausal females aged between = 45 and = 70 years and/or males aged between = 40 years and = 70 years. Patients should have suitable veins for cannulation or repeated venipuncture.
- •Patients diagnosed with T2DM for at least the last 6 months, based on American Diabetes Association 2016 standards.
- •Patients on no other anti-diabetic drug treatment, or on stable maximum 3000 mg daily dose metformin treatment and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months
- •HbA1c levels =6.0% (=42 mmol/mol) and =9.0% (75 mmol/mol)
- •Body mass index (BMI) = 38 kg/m2
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •Any of clinically significant disease or disorder including a recent cardiovascular event
- •Diagnosis of Type 1 Diabetes Mellitus, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus
- •Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula)
- •History of drug abuse or alcohol abuse in the past 12 months
- •Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis
- •Contraindications to dapagliflozin according to the local label
- •Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men.
- •Use of anti-coagulant treatment
- •Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity
- •Use of loop diuretics
- •Regular smoking /nicotine use
- •Any contra-indication to magnetic resonance imaging scanning
- •Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.
研究者
相似试验
已完成
4 期
DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus PatientsdiabetesNL-OMON46385Astra Zeneca60
已完成
4 期
MAASFLEX: A Double-Blind, Randomized, Phase IV, Mechanistic, Placebo-Controlled, Cross-Over, Single-Center Study to Evaluate the Effects of 2 Weeks Dapagliflozin Treatment on Nocturnal Substrate Oxidation, Glucose Metabolism and Muscle Mitochondrial Function in Individuals with Impaired Glucose HomeostasisprediabetesNL-OMON55824niversiteit Maastricht57
进行中(未招募)
1 期
Effects of 2 Weeks treatment with Dapagliflozin in subjects with an Impaired Glucose Homeostasis on Nocturnal substrate oxidatioStudy to investigate the effect of dapagliflozin treatment on nocturnal substrate oxidation in overweight and obese subjects with a disrupted glucose homeostasisEUCTR2018-003283-31-NLSchool of Nutrition and Translational research in Metabolism (NUTRIM), Maastricht University17
已完成
2 期
A Phase II/III, Randomized, Single Blinded, Active Controlled Study to Evaluate the Immunogenicity and Safety of inactivated Japanese encephalitis Vaccine in healthy volunteersCTRI/2011/07/001855Bharat Biotech Intl Ltd600
进行中(未招募)
不适用
Mepolizumab for the treatment of severe asthmaEUCTR2012-001251-40-Outside-EU/EEAGlaxoSmithKline Research and Development Limited540
